Search results for "Raf"

showing 10 items of 11050 documents

Analysis of interleukin-6 and interleukin-8 in lung transplantation: correlation with nitric oxide administration.

2008

Introduction and Objectives. Primary graft dysfunction (PGD) following lung transplantation (LT) is associated with an activation of the inflammatory cascade and release of cytokines. Inhaled nitric oxide (iNO) provides specific pulmonary vasodilatation and improves oxygenation. Our objective was to verify whether administering iNO to LT patients modified the blood and bronchoalveolar lavage (BAL) interleukin (IL)-6 and -8 levels in the event of PGD. Materials and Methods. Thirty-two LT patients were randomized to the iNO treatment or the control group. Patients in the first group were given 10 ppm of iNO from the start of LT until 48 hours afterward. BAL and peripheral arterial blood sampl…

AdultGraft Rejectionmedicine.medical_specialtyAdolescentmedicine.medical_treatmentNitric OxideGastroenterologyNitric oxidechemistry.chemical_compoundYoung AdultPostoperative ComplicationsInternal medicineAdministration InhalationmedicineLung transplantationHumansInterleukin 6AgedInflammationTransplantationLungmedicine.diagnostic_testbiologybusiness.industryInterleukin-6Interleukin-8Interleukinrespiratory systemMiddle AgedBronchodilator AgentsTransplantationBronchoalveolar lavagemedicine.anatomical_structurechemistryAnesthesiabiology.proteinArterial bloodSurgerybusinessLung TransplantationTransplantation proceedings
researchProduct

DR(high+)CD45RA(-)-Tregs potentially affect the suppressive activity of the total Treg pool in renal transplant patients.

2011

Recent studies show that regulatory T cells (Tregs) play an essential role in tolerance induction after organ transplantation. In order to examine whether there are differences in the composition of the total CD4(+)CD127(low+/-)FoxP3(+)- Treg cell pool between stable transplant patients and patients with biopsy proven rejection (BPR), we compared the percentages and the functional activity of the different Treg cell subsets (DR(high+)CD45RA(-)-Tregs, DR(low+)CD45RA(-)-Tregs, DR(-)CD45RA(-)-Tregs, DR(-)CD45RA(+)-Tregs). All parameters were determined during the three different periods of time after transplantation (0-30 days, 31-1,000 days, >1,000 days). Among 156 transplant patients, 37 pat…

AdultGraft Rejectionmedicine.medical_specialtymedicine.drug_classClinical Research DesignImmune Cellslcsh:Medicinechemical and pharmacologic phenomenaMonoclonal antibodyT-Lymphocytes RegulatoryOrgan transplantationInterleukin-7 Receptor alpha SubunitYoung AdultT-Lymphocyte SubsetsBiopsymedicineHumanslcsh:ScienceKidney transplantationAgedKidneyMultidisciplinarymedicine.diagnostic_testbusiness.industrylcsh:RInterleukin-2 Receptor alpha Subunithemic and immune systemsForkhead Transcription FactorsHLA-DR AntigensMiddle AgedImmunologic Subspecialtiesmedicine.diseaseKidney TransplantationTransplant rejectionTransplantationTolerance inductionmedicine.anatomical_structureNephrologyImmunologyLeukocyte Common AntigensMedicinelcsh:QClinical ImmunologySurgerybusinessResearch ArticlePloS one
researchProduct

Uterus transplantation trial: 1-year outcome

2014

Objective To report the 12-month outcome of seven patients with viable uteri after uterus transplantation (UTx). Design Prospective observational study. Setting University hospital. Patient(s) Seven patients with absolute uterine infertility and viable uteri for 12 months after live-donor UTx. Intervention(s) Predetermined immunosuppression was with tacrolimus and mychophenolate mofetil (MMF) during 6 months, whereupon MMF should be withdrawn. Frequent ultrasound examinations were performed to assess uterine appearance and uterine artery blood flow. Cervical biopsies (for histological detection of rejection) were obtained at preset time points, with temporary adjustments of immunosuppressio…

AdultGraft Rejectionmedicine.medical_specialtymedicine.medical_treatmentUterusUrologyAzathioprineMenstruationsmedicine.arteryUterus transplantationHumansMedicineLongitudinal StudiesProspective StudiesUterine arterybusiness.industryUterusFertility PreservationObstetrics and GynecologyImmunosuppressionOrgan TransplantationTacrolimusSurgeryTransplantationTreatment Outcomemedicine.anatomical_structureReproductive MedicineFemalebusinessInfertility FemaleImmunosuppressive Agentsmedicine.drugFertility and Sterility
researchProduct

Selective Depletion of Alloreactive T Lymphocytes Using Patient-Derived Nonhematopoietic Stimulator Cells in Allograft Engineering

2008

Background. Selective depletion of alloreactive T cells in vitro results in efficient graft-versus-host disease prophylaxis in allogeneic hematopoietic stem-cell transplantation, but it is accompanied by increased recurrence of leukemia. To spare donor T-cell-mediated graft-versus-leukemia immunity against hematopoiesis-restricted minor histocompatibility (minor-H) antigens, we explored the use of patient-derived nonhematopoietic antigen-presenting cells (APC) as allogeneic stimulators for selective allodepletion in leukemia-reactive donor T-cell lines. Methods. Primary keratinocytes, dermal fibroblasts, and bone marrow fibroblasts were generated from skin biopsies and diagnostic bone marro…

AdultKeratinocytesT-LymphocytesLymphocyteGraft vs Host DiseaseHuman leukocyte antigenLymphocyte DepletionInterferon-gammaTumor Necrosis Factor Receptor Superfamily Member 9AntigenAntigens CDmedicineHumansTransplantation HomologousSkinB-LymphocytesHLA-D AntigensTransplantationCD40Tissue EngineeringbiologyHistocompatibility Antigens Class IHematopoietic Stem Cell TransplantationDermisT lymphocyteFibroblastsmedicine.diseaseLeukemiamedicine.anatomical_structureEpidermal CellsImmunologybiology.proteinBone marrowEpidermisCD8Transplantation
researchProduct

Frequent Alteration of the Yin Yang 1/Raf-1 Kinase Inhibitory Protein Ratio in Hepatocellular Carcinoma

2011

The transcription factor Yin Yang 1 (YY1) can favor several aspects of tumorigenesis. In turn, Raf-1 Kinase Inhibitor Protein (RKIP) inhibits the oncogenic activities of MAPK and NF-κB pathways and promotes drug-induced apoptosis. Mutual influences between YY1 and RKIP may exist, and there are already separate evidences that relevant increases in YY1 and reductions in RKIP occur in hepatocellular carcinoma (HCC). However, the levels of the two factors have never been concomitantly examined in HCC. We evaluated by RT-PCR the mRNA levels of YY1, YY1AP, RKIP, and survivin in 35 clinical HCCs (91% HCV-related), in their adjacent cirrhotic tissues and in 6 healthy livers. Immunohistochemical ana…

AdultLiver CirrhosisMaleMAPK/ERK pathwayCarcinoma HepatocellularSettore MED/09 - Medicina InternaSurvivinCell Cycle ProteinsPhosphatidylethanolamine Binding ProteinSettore MED/08 - Anatomia PatologicaBiologymedicine.disease_causeBiochemistryInhibitor of Apoptosis ProteinsSurvivinGeneticsmedicineHumansRNA MessengerHepatocellular carcinomaYY1RKIPMolecular BiologyTranscription factorYY1 Transcription FactorAgedAged 80 and overSettore MED/12 - GastroenterologiaHepatocellular carcinoma Yin Yang 1 Raf-1 Kinase Inhibitor Protein Yin Yang 1-associated proteinKinaseYY1Liver NeoplasmsNuclear ProteinsMiddle AgedHCCSmedicine.diseaseGene Expression Regulation NeoplasticLiverHepatocellular carcinomaembryonic structuresSettore BIO/14 - FarmacologiaCancer researchMolecular MedicineFemaleSettore SECS-S/01 - StatisticaCarcinogenesisTranscription FactorsBiotechnologyOMICS: A Journal of Integrative Biology
researchProduct

Safety and Efficacy of Sorafenib in Patients With Advanced Hepatocellular Carcinoma in Consideration of Concomitant Stage of Liver Cirrhosis

2009

GOALS AND BACKGROUND: The multikinase inhibitor sorafenib provides survival benefit for patients with advanced hepatocellular carcinoma (HCC) and liver cirrhosis (LCI) Child-Pugh A. We report our experiences with sorafenib in advanced HCC, particularly in patients with LCI Child-Pugh B/C, where only limited data are available in regard to safety and efficacy of sorafenib. METHODS: Thirty-four patients with advanced HCC were treated with sorafenib regardless of liver function and prior anticancer therapy. Adverse events (AEs) were graded using Common Toxicity Criteria version 3.0, tumor response was assessed according to Response Evaluation Criteria in Solid Tumors. RESULTS: Fifteen patients…

AdultLiver CirrhosisMaleNiacinamideSorafenibmedicine.medical_specialtyCarcinoma HepatocellularTime FactorsCirrhosisPyridinesAntineoplastic AgentsKaplan-Meier EstimateRisk AssessmentSeverity of Illness IndexGastroenterologyInternal medicinemedicineCarcinomaHumansProspective StudiesProtein Kinase InhibitorsAgedAged 80 and overbusiness.industryPatient SelectionPhenylurea CompoundsBenzenesulfonatesLiver NeoplasmsGastroenterologyCancerMiddle AgedSorafenibmedicine.diseasedigestive system diseasesSurgeryTreatment OutcomeResponse Evaluation Criteria in Solid TumorsHepatocellular carcinomaConcomitantFemaleLiver functionbusinessmedicine.drugJournal of Clinical Gastroenterology
researchProduct

Cirrhosis of mixed etiology (hepatitis C virus and alcohol): Posttransplantation outcome-Comparison with hepatitis C virus-related cirrhosis and alco…

2008

Hepatitis C virus (HCV)-related liver disease is enhanced by alcohol consumption. Of HCV-related liver transplantation (LT) recipients, 25% have a history of alcohol intake. The purpose of this research was to determine whether LT outcome differs between patients with cirrhosis of mixed etiology compared to HCV or alcohol alone. Of 494 LT (1997-2001), recipient/donor features, post-LT histological, metabolic complications [hypertension, diabetes-diabetes mellitus (DM)], and de novo tumors were compared in 3 groups [HCV-related cirrhosis = 170 (HCV group), alcohol-related cirrhosis (alcohol group) = 107, and cirrhosis of mixed etiology (mixed group) = 60]. Protocol biopsies were done in HCV …

AdultLiver CirrhosisMalemedicine.medical_specialtyCirrhosisHepatitis C virusmedicine.medical_treatmentHepacivirusLiver transplantationmedicine.disease_causeGastroenterologyBody Mass IndexLiver diseasePostoperative ComplicationsLiver Cirrhosis AlcoholicInternal medicineHumansMedicineAgedTransplantationHepatologybusiness.industryIncidence (epidemiology)Graft Survivalvirus diseasesMiddle Agedmedicine.diseaseHepatitis Cdigestive system diseasesLiver TransplantationTreatment OutcomeHepatocellular carcinomaEtiologyFemaleSurgerybusinessBody mass indexImmunosuppressive AgentsLiver Transplantation
researchProduct

Physical injury and depression in six low- and middle-income countries: A nationally representative study.

2019

BACKGROUND: Studies on the association between physical injury and depression in low- and middle-income countries (LMICs) are scarce. Therefore, our goal was to analyze the association between physical injury and depression using nationally representative data from six LMICs. METHODS: Cross-sectional data from the Study on Global Ageing and Adult Health (SAGE) survey (2007-2010) were analyzed (N?=?42,489). Questions based on the World Mental Health Survey version of the Composite International Diagnostic Interview were used for the endorsement of past 12-month DSM-IV depression. Any injury in our analysis referred to having experienced traffic injury or other injury in the past 12 months. M…

AdultMale*Low- and middle-income countries[SDV]Life Sciences [q-bio]Logistic regressionOdds*Retrospective study03 medical and health sciences0302 clinical medicineEnvironmental healthPrevalenceHumansMedicineDeveloping CountriesPovertyDepression (differential diagnoses)*Physical injurybusiness.industryDepressionRetrospective cohort studyMiddle AgedTraffic injury*DepressionHealth SurveysCausalityMental health3. Good health030227 psychiatryPsychiatry and Mental healthClinical PsychologyRetrospective studyCross-Sectional StudiesLogistic ModelsLow- and middle-income countrieLow and middle income countriesMultivariate AnalysisWounds and InjuriesFemalePhysical injurybusiness030217 neurology & neurosurgery
researchProduct

Preemptive antiviral therapy for CMV infection in allogeneic stem cell transplant recipients guided by the viral doubling time in the blood

2015

Preemptive antiviral therapy for CMV infection in allogeneic stem cell transplant recipients guided by the viral doubling time in the blood

AdultMale0301 basic medicineAdolescent030106 microbiologyCytomegalovirusVirus ReplicationAntiviral AgentsYoung Adult03 medical and health sciences0302 clinical medicineHumansTransplantation HomologousMedicineDoubling timeProgenitor cellGanciclovirAgedTransplantationbusiness.industryHematopoietic Stem Cell TransplantationAntiviral therapyHematologyMiddle Agedmedicine.diseaseTransplantationGraft-versus-host diseaseCytomegalovirus InfectionsDNA ViralImmunologyFemaleStem cellbusiness030215 immunologyBone Marrow Transplantation
researchProduct

Adipose tissue-derived mesenchymal stromal cells as part of therapy for chronic graft-versus-host disease: A phase I/II study

2017

Abstract Background aims Despite the efficacy of allogeneic hematopoietic stem cell transplantation (allo-HSCT), the procedure is still associated with high toxicity in patients with refractory graft-versus-host disease (GvHD). Mesenchymal stromal cells (MSCs) are a new mode of therapy in the context of allo-HSCT. The objective of this study was to evaluate the safety and feasibility of the use of adipose tissue–derived MSCs (AT-MSCs) in patients with chronic GvHD. Methods Fourteen patients with moderate (n = 7) or severe (n = 7) chronic GvHD received 1 × 106/kg (group A, n = 9) or 3 × 106/kg (group B, n = 5) AT-MSCs with cyclosporine and prednisone as first-line therapy. Results Ten of the…

AdultMale0301 basic medicineCancer Researchmedicine.medical_specialtymedicine.medical_treatmentImmunologyGraft vs Host DiseaseAdipose tissueContext (language use)DiseaseHematopoietic stem cell transplantationMesenchymal Stem Cell TransplantationGastroenterology03 medical and health sciencesPrednisoneInternal medicinemedicineHumansImmunology and AllergyGenetics (clinical)TransplantationTumor Necrosis Factor-alphabusiness.industryMesenchymal stem cellMesenchymal Stem CellsCell BiologyMiddle Agedmedicine.diseaseKiller Cells NaturalTreatment Outcome030104 developmental biologyGraft-versus-host diseaseAdipose TissueOncologyToxicityImmunologyCyclosporinePrednisoneFemalebusinessImmunosuppressive Agentsmedicine.drugCytotherapy
researchProduct